The Clinical Application of COX-2 Inhibitors May Strengthen the Sensitivity of Renal Cell Carcinoma to Immunotherapy

Jinfeng Li,Guomin Wang,Yiwei Chu,Ruiming Rong,Tongyu Zhu
DOI: https://doi.org/10.1016/j.mehy.2008.06.010
IF: 4.7
2008-01-01
Medical Hypotheses
Abstract:Renal cell carcinoma (RCC) remains a difficult management problem, because of the high metastatic rate and insensitivity of metastatic RCC to the traditional cytokine-based immunotherapy such as interleukin-2 and interferon-alpha. Regulatory T cells had a crucial role in impeding immune surveillance against cancer and hampering the development of effective anti-tumor immunity. At the same time cyclooxygenase-2 derived prostaglandin E2 played an important role in the transformation of regulatory T cells and could strengthen the inhibitory function of regulatory T cells. Previous experiment characterized that cyclooxygenase-2 was highly expressed in RCC. Herein, we draw the hypothesis that cyclooxygenase-2 inhibition may dampen the transformation of regulatory T cells and in turn contribute to eradicating RCC by the immune system. The clinical application of cyclooxygenase-2 inhibitors may strengthen the sensitivity of RCC to cytokine-based immunotherapy.
What problem does this paper attempt to address?